PRESENTATION

Q4 2024 — Presentation

Q4 2024PDF · 35 pages2.9 MB
Merck
Q4 2024 Earnings
February 4, 2025

-- 1 of 35 --

Agenda
2
Question & Answer
Session
Financial Results and
Outlook
Caroline Litchfield
Chief Financial Officer
Research Update
Dr. Dean Li
President, Merck
Research Laboratories
Strategy and Business
Update
Rob Davis
Chairman and Chief
Executive Officer

-- 2 of 35 --

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of
the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and
are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary
regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency
exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward
health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including
obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the
exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report
on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).

-- 3 of 35 --

Strategy and
Business Update
Rob Davis
Chairman and Chief Executive Officer

-- 4 of 35 --

Committed to saving and improving lives around the world
5
Nearly half a billion
people reached
with our medicines
and vaccines
in 2024

-- 5 of 35 --

Delivered on our key strategic priorities
6
Advanced the pipeline to meet
patient unmet need
Executed on strategic business
development to augment pipeline
Achieved strong commercial and
financial performance
Created long-term value for patients
and shareholders

-- 6 of 35 --

0
10,000
20,000
30,000
40,000
50,000
60,000
70,000
2022 	2023 	2024 	2025
2024 performance1 and 2025 initial guidance
7
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Merck does not exclude expenses for upfront and milestone payments related to certain collaborations and licensing
agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. Fourth quarter of 2024 includes a charge of
$0.23 per share for such items. Fourth quarter of 2023 includes a charge of $1.69 per share for such items. Full year non-GAAP results for 2024, 2023 and 2022 include $1.28, $6.21, $0.22 per
share of such charges, respectively. Full-year 2025 guidance includes ~$0.09 per share of such charges. 3. Full year 2024 GAAP EPS $6.74. 4. Fourth quarter of 2024 GAAP EPS $1.48.
$15.6B
+7%
+9% ex-Exchange
Q4 Worldwide Sales
$1.72
Q4 Non-GAAP EPS4
$60.1B
+1%	$5.37
Full Year Sales
Full Year Non-GAAP EPS2,3
$59.3B
+22%
2022 	2023 	2024 	2025
$1.51
$7.48 	$7.65
GUIDANCE RANGE
$64.1B - $65.6B
+0% - +2%
GUIDANCE RANGE
$8.88 - $9.03
$64.2B
+7%

-- 7 of 35 --

Update on GARDASIL in China
8
• 	Market dynamics remain challenging
• 	Temporarily pausing shipments beginning in February through
at least mid-year to accelerate inventory reduction
• 	Expect strong growth in 2H25, 2026 and 2027, irrespective of
GARDASIL in China
Confidence in ability to successfully navigate the
KEYTRUDA LOE period remains unchanged

-- 8 of 35 --

Advancing and broadening our diverse pipeline
9
Oncology 	Cardiometabolic	Infectious Disease
• 	FDA acceptance of BLA for
clesrovimab to help protect
infants from RSV
• 	Topline results for islatravir +
doravirine for HIV treatment
• 	Positive topline results for
subcutaneous pembrolizumab
• 	Licensed MK-2010, a PD-1/VEGF
bispecific antibody, from LaNova
• 	Positive topline results for
WINREVAIR from ZENITH trial
• 	Licensed MK-4082, an oral GLP-1
receptor agonist, from Hansoh

-- 9 of 35 --

Evolving to a more diversified commercial portfolio with robust Phase 3
development program
10
enlicitide decanoate
Oral PCSK9i
bomedemstat
LSD1i
ifinatamab deruxtecan1
B7H3 ADC
pembrolizumab +
berahyaluronidase alfa
SC administration
raludotatug deruxtecan1
CDH6 ADC
sacituzumab
tirumotecan3
TROP2 ADC
tulisokibart
TL1A
MK-3000
Tetravalent tri-specific
antibody
clesrovimab
RSV mAb
islatravir + doravirine
NRTTI
patritumab deruxtecan1
HER3 ADC
zilovertamab vedotin
ROR1 ADC
pembrolizumab +
quavonlimab
CTLA-4
nemtabrutinib
BTKi
2026-2027	2024-2025
opevesostat
CYP11A1i
MK-10844
KRAS G12Ci
V9405
INT
2028+
20 new growth drivers, almost all of which have blockbuster potential
Oncology 	Infectious Disease / Vaccines
Cardiometabolic 	Ophthalmology / Immunology
Note: Timing reflects primary completion date on clinicaltrials.gov. Excludes ongoing Phase 3 studies for marketed products including
KEYTRUDA, Lenvima, Lynparza, Verquvo, LAGEVRIO and WELIREG.
1. Collaboration with Daiichi Sankyo 2. Collaboration with Gilead 3. Collaboration with Kelun Biotech
4. Collaboration with Taiho and Astex 5. Collaboration with Moderna
islatravir + lenacapavir2
NRTTI

-- 10 of 35 --

Updated Opportunity1
>$25B
Expanding diverse pipeline to drive patient impact and value creation
11
Oncology
Cardiometabolic
Immunology
HIV
Ophthalmology
~$15B
>$5B
>$5B
Multibillion
+
Infectious Disease / Vaccines
• 	Including clesrovimab, V181 and others
Animal Health
• 	Expect revenue to more than double by
the mid-2030s
Early-Phase Programs
• 	Many advancing to Phase 2 in 2025/2026
Business Development
• 	Significant capacity to further augment
pipeline
1. All dollar figures above are non-risk adjusted annual sales by the mid 2030s

-- 11 of 35 --

Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer

-- 12 of 35 --

Strong Q4 and 2024 worldwide sales growth
13
Q4 2024 WORLDWIDE SALES1
$15.6B+7% growth
+9% ex-Exchange 2
$14.0B
+7% growth
+8% ex-Exchange 2
Human Health
$1.4B
+9% growth
+13% ex-Exchange 2
Animal Health
1. Worldwide Sales includes Other Revenue. 2. ~1 percentage point of the negative impact of foreign exchange for Human Health sales, ~2 percentage points of the negative impact of
foreign exchange for Worldwide sales, and ~3 percentage points of the negative impact of foreign exchange for Animal Health, were due to devaluation of the Argentine peso, which
were largely offset by inflation-related price increases, consistent with practice in that market.
FULL YEAR WORLDWIDE SALES1
$64.2B+7% growth
+10% ex-Exchange 2
Merck

-- 13 of 35 --

Oncology: KEYTRUDA continues to grow globally
14
Growth rates exclude the impact of foreign exchange.
1. ~2 percentage point negative impact of foreign exchange were due to devaluation of Argentine peso,
which were largely offset by inflation-related price increases, consistent with practice in that market.
• KEYTRUDA sales of $7.8B increased 21%1 ,
driven by continued robust global demand
from metastatic indications and uptake from
earlier stage cancers
– In the U.S., growth reflects increased uptake from
KN-A39 in locally advanced or metastatic
urothelial cancer and KN-868 in primary advanced
or recurrent endometrial cancer, as well as earlier
stage NSCLC and TNBC
– Outside the U.S., growth reflects continued
uptake in earlier stage cancers, including high-
risk, early-stage TNBC, as well as demand from
metastatic indications
$4.2B
+20%
$3.4B
+31%
$5.3B
+30%
4Q22 	4Q23 	4Q24
$5.5B
+26%
$7.8B
+21%
$6.6B
+22%

-- 14 of 35 --

Oncology: Strength across broad portfolio
15
• WELIREG sales more than doubled, driven by
increased uptake in certain adult patients with
previously treated advanced RCC in the U.S.
• Lynparza 1 sales grew 18%, primarily due to
higher global demand
• Lenvima 2 sales grew 14%, primarily due to
timing of shipments in certain international
markets
$181M
+15%
$151M
+57%
Growth rates exclude the impact of foreign exchange.
1. In collaboration with AstraZeneca 2. In collaboration with Eisai
4Q22 	4Q23 	4Q24
$315M
+8%
$292M
+14%
$365M
+18%
4Q22 	4Q23 	4Q24
$226M
+5%
$216M
+9%
$255M
+14%
4Q22 	4Q23 	4Q24
$72M
+78%$40M
+245%
$160M
+123%

-- 15 of 35 --

4Q22 	4Q23 	4Q24
$1.7B
+40%
4Q22 	4Q23 	4Q24
$1.9B
+27%
Vaccines: Broad vaccines portfolio driving global impact
16
• GARDASIL sales of $1.6B decreased 18%,
driven by lower demand in China
– In the U.S., sales benefitted from price and
demand, partially offset by CDC purchasing
patterns
– Outside the U.S. and China, double digit sales
growth driven by higher overall demand including
catch-up cohort in Japan
• VAXNEUVANCE sales of $161M declined 9%,
as growth from ongoing launches in
international markets more than offset by
competitive pressures in the U.S.
• CAPVAXIVE sales of $50M, driven by demand
from retail pharmacy channel
Growth rates exclude the impact of foreign exchange.
$1.6B
-18%
$1.5B
+6%
$138M
$176M
+26% $161M
-9%

-- 16 of 35 --

Cardiovascular: Successful ongoing launch of WINREVAIR
17
Global Q4 sales of $200M
Patients
• 	Achieved coverage for >60% of lives since launch
• 	Many payors established coverage policies consistent with the label or
STELLAR criteria
• 	~1,500 new patients prescribed in the quarter
• 	~5,200 total patients prescribed since launch
• 	~80% of prescribed patients receive commercial product
• 	~3,900 commercial patients started treatment since launch
• 	>22,000 total prescriptions filled since launch
• 	>900 physicians have written at least one prescription since launch
• 	Most prescribers are from large academic centers or larger private practices
• 	Increasing percentage of prescriptions are for patients not on prostacyclin
background therapy
Ex-U.S.
U.S.
• 	Launch is on track in Germany
• 	Anticipate securing reimbursement in other European countries in 2H25
Prescribers
Payors

-- 17 of 35 --

Animal Health: Strong growth across livestock and companion animal
18
• Animal Health sales increased 13% 1 to $1.4B
– Livestock sales grew 14%, driven by higher
demand for poultry products, inclusion of sales
from the recently expanded aqua portfolio, and
price
– Companion Animal sales growth of 10% reflects
price
4Q22 	4Q23 	4Q24
$1.2B
+6%
$1.3B
+4%
$1.4B
+13%
Growth rates exclude the impact of foreign exchange.
1. ~3 percentage point negative impact of foreign exchange were due to devaluation of Argentine peso,
which were largely offset by inflation-related price increases, consistent with practice in that market.

-- 18 of 35 --

Q4 2024 non-GAAP financial results summary1
19
Q4 2024 	Q4 2023 	Change Change
Ex-FX
Sales 	$15.6 	$14.6 	+7% 	+9%
Non-GAAP Gross Margin 	80.8% 	77.2% 	+3.6pts 	+3.3pts
Non-GAAP Operating
Expenses $7.4 	$11.6 	-36% 	-36%
Non-GAAP Tax Rate 	16.2% 	114.2% 	N/M 	N/A
Non-GAAP EPS2,3 $1.72 	$0.03 	>100% 	>100%
$ in billions, except EPS amounts
1. Merck is providing certain 2024 and 2023 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business
performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual
employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a
substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q4 2024 includes a
charge of $0.23 per share for the LaNova and Hansoh transactions. Q4 2023 includes a charge of $1.69 per share for the collaboration with Daiichi Sankyo. 3. Q4 2024 GAAP EPS of $1.48

-- 19 of 35 --

Initial 2025 financial outlook
1. Guidance does not assume any additional significant potential business development transactions.
20
Guidance 	Key Assumptions
Revenue 	$64.1B to $65.6B
• 	Assumes ~2 percentage point FX headwind
• 	Implies +0% to +2% nominal (+2% to +4% ex-FX)
• 	Assumes no further shipments of GARDASIL to China at the low-end
and less than $1B at the high-end
Non-GAAP
Gross Margin Rate ~82.5%
Non-GAAP
Operating Expenses1 	$25.4B to $26.4B • 	Includes $300M anticipated milestone payment to LaNova
associated with technology transfer for MK-2010
Other (Income) / Expense 	~$300M to ~$400M of expense
Tax Rate 	~16.0% to 17.0%
Shares Outstanding 	~2.53B
Non-GAAP EPS1 	$8.88 to $9.03 • 	Includes ~$0.09 charge related to anticipated milestone payment to
LaNova associated with technology transfer for MK-2010
• 	Assumes a negative impact from FX of ~$0.35

-- 20 of 35 --

Key modeling considerations
21
GARDASIL
• 	Withdrawing $11B target given uncertain timing of economic recovery in China
• 	Growth expectations outside of China remain unchanged
• 	Well-positioned to drive strong growth beyond 2025
KEYTRUDA • 	In the U.S., benefitted from ~$200M of wholesaler buy-in during 4Q24, which is
expected to reverse in 1Q25
Medicare
Part D
Redesign
• 	Anticipate ~$400M negative impact related to Medicare Part D redesign, primarily
affecting WINREVAIR, WELIREG, Lynparza and Lenvima
JANUVIA
Family1
• 	Lowered list price in the beginning of 2025 to more closely align with net price
• 	Reduced list price will lower rebate amount paid to Medicaid
• 	Expect higher net sales in the U.S. in 2025
• 	Expect to benefit from continued strength in Oncology and Animal Health, as well as
contributions from new product launches
• 	Expect roughly flat YoY revenues in 1H25 and strong YoY growth in 2H25
Sales
1. JANUVIA Family includes JANUVIA, JANUMET and JANUMET XR

-- 21 of 35 --

22
Continue to invest in the
pipeline and business while
augmenting the pipeline
with value-enhancing
business development
$3.2
$0.9
$2.0
$0.2 $0.5
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase
Q4 Spend ($ in billions) 1
1. Reflects quarter spend
2. Reflects R&D excluding Business Development
Remain committed to balanced capital allocation strategy
Capital allocation order of priority
2

-- 22 of 35 --

Research Update
Dr. Dean Li
President, Merck Research Laboratories

-- 23 of 35 --

Important updates from across our cardiometabolic pipeline
24
Foundational study supported initial regulatory approval for
WINREVAIR as first-in-class treatment for PAH
‒ Submitted for approval in Japan
Open-label long-term extension study for patients rolling over from
other studies
WINREVAIR 	MK-4082
• 	Entered exclusive global license agreement
with Hansoh to develop preclinical oral
small molecule GLP-1 receptor agonist
• 	Well-positioned to advance combinations
with next-generation agents for weight
loss and cardiometabolic disease
Positive topline results in Phase 3 study in adults with PAH FC III or
IV at high risk of mortality
‒ Stopped early due to overwhelming efficacy in primary endpoint
Phase 3 study in newly diagnosed adults with PAH FC II or III at
immediate or high risk of disease progression
‒ Stopped early and moving to final analysis based on totality of clinical benefit

-- 24 of 35 --

Building on our strong legacy in infectious disease and vaccines
25
RSV
• 	FDA set PDUFA date of June 10th
for clesrovimab, investigational
long-acting monoclonal antibody
to help protect infants from RSV
disease during their first RSV
season
• 	If approved, clesrovimab would
be the first and only single dose
passive immunization for infants
regardless of weight
Vaccines	HIV
• 	Announced topline results from
two Phase 3 trials evaluating
doravirine and islatravir as
once-daily, oral combination
treatment option for adults
living with HIV infection that is
virologically suppressed on
different antiretroviral therapy
regimens
• 	Advancing MK-8527, once-
monthly oral option for PrEP, to
Phase 3 this year
• 	GARDASIL approved in China for
males 9 to 26 years old to help
prevent certain HPV-related
cancers and diseases
• 	Presented new clinical and real-
world data for GARDASIL 9 at
International Papillomavirus
Conference
• 	CHMP in Europe recommended
approval of CAPVAXIVE for
prevention of invasive
pneumococcal disease and
pneumococcal pneumonia in adults

-- 25 of 35 --

Regulatory Developments
Strengthening our leadership in oncology
U.S.
 	• 	Sac-TMT2: FDA granted Breakthrough Therapy Designation for treatment of patients with
advanced or metastatic nonsquamous NSCLC with EGFR mutations whose disease
progressed on or after TKI and platinum-based chemotherapy
China
• 	KN-671: NMPA approved KEYTRUDA regimen1 for neoadjuvant and adjuvant treatment for
certain patients with resectable NSCLC
• 	KN-A18: NMPA approved KEYTRUDA in combination with chemoradiotherapy for treatment
of certain patients with FIGO 2014 Stage III-IVA locally advanced cervical cancer
• 	KN-A39: NMPA approved KEYTRUDA in combination with Padcev for 1L treatment of adult
patients with locally advanced or metastatic urothelial carcinoma
• 	LS-004: NMPA approved WELIREG for treatment of adult patients with certain types of
VHL disease-associated tumors
Japan
 	• 	KN-A18: MHLW approved KEYTRUDA in combination with chemoradiotherapy for
treatment of certain patients with FIGO 2014 Stage III-IVA locally advanced cervical cancer
• 	KN-868: MHLW approved KEYTRUDA in combination with carboplatin and paclitaxel for 1L
treatment of certain patients with primary advanced or recurrent endometrial carcinoma
• 	Fixed dose pembrolizumab +
berahyaluronidase alfa in combination with
chemotherapy met primary pharmacokinetic
endpoints in Phase 3 MK-3475A-D77 trial
PD-1/VEGF bispecific antibody
• 	Exclusive global license with LaNova to
develop MK-2010
Subcutaneous pembrolizumab
• 	More than 20 abstracts presented at ASH 3,
including results from Phase 2 waveLINE-007
study evaluating zilovertamab vedotin, an
investigational ADC targeting ROR1, in
previously untreated patients with diffuse
large B-cell lymphoma
Hematology
1. KEYTRUDA in combination with platinum-containing chemotherapy as neoadjuvant treatment and continued as monotherapy as adjuvant treatment after surgery
2. Collaboration with Kelun Biotech 3. American Society of Hematology Annual Meeting 	26

-- 26 of 35 --

Significant progress across our broad pipeline in 2024
27
>25
>20
Regulatory approvals in major
regions, including
WINREVAIR and CAPVAXIVE
Phase 3 studies initiated across
multiple therapeutic areas “One Pipeline ”
Complementing internal innovation and
discovery efforts with the best external
science through business development
to advance breakthrough science
for patients

-- 27 of 35 --

Select milestones in 2025
28
Medical Meeting Presentations 	Upcoming Data Readouts
Cardiometabolic
• 	WINREVAIR - Phase 3 ZENITH study in PAH at
American College of Cardiology 2025
Infectious Disease
• 	Islatravir + doravirine - Phase 3 MK-8591A-051 and
MK-8591A-052 studies for HIV treatment
Oncology
• 	Subcutaneous pembrolizumab plus berahyaluronidase-
alfa - Phase 3 MK-3475A-D77 study
• 	KEYTRUDA - Phase 3 KN-689 study in locally advanced
HNSCC
• 	Enlicitide decanoate – Phase 3 studies in
hypercholesterolemia
‒ 	CORALreef HeFH (PCD in April)
‒ 	CORALreef AddOn (PCD in July)
‒ 	CORALreef Lipids (PCD in August)
• 	WINREVAIR – Phase 2 study in PH due to LHD
(PCD in October)

-- 28 of 35 --

Q&A
Rob Davis
Chairman and Chief Executive Officer
Dr. Dean Li
President, Merck Research Laboratories
Caroline Litchfield
Chief Financial Officer
Peter Dannenbaum
Senior Vice President, Investor Relations

-- 29 of 35 --

30
Appendix

-- 30 of 35 --

Q4 2024 GAAP financial results summary
31
Q4 2024 	Q4 2023 	Change 	Change Ex-FX
Sales 	$15.6 	$14.6 	+7% 	+9%
Operating Expenses1 $7.4 	$12.4 	-40% 	-40%
Tax Rate 	10.2% 	40.1% 	N/M 	N/A
GAAP Earnings /
(Loss) per Share1 $1.48 	($0.48) 	>100% 	>100%
$ in billions, EPS/LPS amounts
1. 4Q24 GAAP results include a charge of $0.23 per share related to the execution of licensing agreements with LaNova and Hansoh.
4Q23 GAAP results include a charge of $1.69 per share related to the collaboration with Daiichi Sankyo.

-- 31 of 35 --

2024 GAAP financial results summary
32
2024 	2023 	Change 	Change Ex-FX
Sales 	$64.2 	$60.1 	+7% 	+10%
Operating Expenses 	$28.8 	$41.0 	-30% 	-29%
Tax Rate 	14.1% 	80.0% 	N/M 	N/A
GAAP
Earnings per Share $6.74 	$0.14 	>100% 	>100%
$ in billions, EPS amounts

-- 32 of 35 --

33
E
Capital allocation: Trailing twelve months
$12.1
$3.4
$7.8
$4.7 $1.3
$0
$3
$6
$9
$12
$15
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
~$ 20B
Over 5 years, including expanding
manufacturing capacity for Oncology, Vaccines,
and Animal Health. Includes >$11B in the U.S.
Billions
Over the past 12 months
Capital investments
2024 to 2028
Commitment to the dividend
Well-positioned balance sheet
with capacity to fund
additional value-enhancing
business development
opportunities
Order of priority
1. 	Reflects R&D excluding Business Development
2. 	Includes BD payments reflected in operating cash flow
2
1
E
$1.80 	$1.84 	$1.88 	$1.92
$2.20 $2.44 $2.60 $2.76 $2.92 	$3.08
2015 	2016 	2017 	2018 	2019 	2020 	2021 	2022 	2023 	2024
Dollars per share
+2% 	+2% 	+2% 	+2%
+11%
+15%
+7% +6% +6% 	+5%

-- 33 of 35 --

Driving value for patients and shareholders by progressing our pipeline
• 	In the U.S., the FDA:
o Accepted for priority review the sNDA for WELIREG for the treatment of adult and pediatric (12 years and older)
patients with advanced, unresectable, or metastatic PPGL
o Accepted the BLA for clesrovimab, an investigational prophylactic long-acting monoclonal antibody designed to
protect infants from RSV disease during their first RSV season
o Granted Breakthrough Therapy Designation to sac-TMT for the treatment of patients with advanced or
metastatic nonsquamous NSCLC with EGFR mutations whose disease progressed on or after TKI and platinum-
based chemotherapy
• 	In the EU, the CHMP adopted a positive opinion for:
o CAPVAXIVE for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in
individuals 18 years of age and older based on the Phase 3 STRIDE studies
o WELIREG for the treatment of adult patients with VHL disease who require therapy for associated, localized RCC,
CNS hemangioblastomas, or pNET, and for whom localized procedures are unsuitable based on LITESPARK-004
o WELIREG for the treatment of adult patients with advanced clear cell RCC that progressed following two or more
lines of therapy that included a PD-1 or PD-L1 inhibitor and at least two VEGF targeted therapies based on
LITESPARK-005
o KEYTRUDA in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult
patients with unresectable non-epithelioid malignant pleural mesothelioma based on IND.227/KN-483
• 	In China, the NMPA approved:
o GARDASIL for use in males 9-26 years of age to help prevent certain HPV-related cancers and diseases
o KEYTRUDA in combination with platinum-containing chemotherapy as neoadjuvant treatment and then
continued as monotherapy as adjuvant treatment after surgery for patients with resectable stage II, IIIA, or IIIB
NSCLC based on KN-671
o WELIREG for the treatment of adult patients with VHL disease who require therapy for associated RCC, CNS
hemangioblastomas or pNET, not requiring immediate surgery based on LITESPARK-004
o KEYTRUDA in combination with enfortumab vedotin for the treatment of adult patients with locally advanced or
metastatic urothelial cancer based on KN-A39
o KEYTRUDA for the treatment of certain types of locally advanced cervical cancer based on KN-A18
• 	In Japan, the MHLW approved:
o KEYTRUDA for the treatment of advanced and recurrent endometrial cancer in combination with chemotherapy
based on KN-868/NRG-GY018
o KEYTRUDA in combination with CCRT for the treatment of locally advanced cervical cancer based on KN-A18
Announced:
• 	Phase 3 switch trials evaluating doravirine/islatravir met primary efficacy
hypotheses in adults with HIV-1 infection that is virologically suppressed on
different antiretroviral therapy regimens
• 	Phase 3 ZENITH trial evaluating WINREVAIR was stopped early after
meeting its primary endpoint of time to first morbidity or mortality event
for the treatment of patients with PAH FC III or IV at high risk of mortality at
interim analysis
• 	Phase 3 HYPERION trial evaluating WINREVAIR in recently diagnosed
adults with PAH FC II or III at intermediate or high risk of disease
progression will be stopped early due to the positive results from the
interim analysis of the ZENITH trial and a review of the totality of data
from the WINREVAIR clinical program to date
• 	Phase 3 MK-3475A-D77 trial met its dual primary PK endpoints as
subcutaneous administration of pembrolizumab together with
berahyaluronidase alfa administered with chemotherapy for the first-line
treatment of adult patients with metastatic NSCLC
Presented data for:
• 	Phase 3 OlympiA trial evaluating Lynparza at the 2024 San Antonio Breast
Cancer Symposium showing long-term data on OS, IDFS and DDFS for
people with gBRCAm HER2-negative high-risk early breast cancer
• 	Approved and investigational medicines across multiple hematologic
malignancies at the American Society of Hematology (ASH) Annual Meeting
and Exposition including for zilovertamab vedotin (ROR1 ADC),
nemtabrutinib (BTKi), bomedemstat (LSD1i), and KEYTRUDA
• 	GARDASIL 9 at the International Papillomavirus Conference (IPVC) 2024
including new clinical and real-world data evaluating the burden and
incidence of certain HPV-related cancers and diseases
Key regulatory milestones since the last earnings call:
34
Key data & clinical advancements since the last earnings call:

-- 34 of 35 --

Broad and innovative pipeline to address significant unmet medical needs
Phase 2 	Phase 3 	Under regulatory review
KEYTRUDA (MK-3475)
Advanced Solid Tumors
Prostate
MK-3475A (pembrolizumab +
berahyaluronidase alfa)
cSCC
Hematological Malignancies
MK-5890 (boserolimab)2
Neoplasm Malignant
MK-5909 (raludotatug
deruxtecan)1
Bladder
Cervical
Endometrial
Ovarian
RCC
WELIREG (MK-6482)3
Breast
Endometrial
Esophageal
HCC
LYNPARZA
(MK-7339)1,3
Advanced Solid Tumors
V940 1,2
Bladder
RCC
MK-1022 (patritumab deruxtecan)1
Biliary
Bladder
Cervical
CRC
Endometrial
Esophageal
Gastric
HCC
HNSCC
Melanoma
Ovarian
Pancreas
Prostate
MK-1308 (quavonlimab)2
NSCLC
MK-1308A (quavonlimab
+pembrolizumab)
CRC
MK-2400 (ifinatamab deruxtecan)1
Biliary
Bladder
Breast
Cervical
CRC
Endometrial
Esophageal
HCC
HNSCC
Melanoma
Ovarian
Pancreas
MK-2870 (sacituzumab
tirumotecan)1,3
Biliary
CRC
Neoplasm Malignant
Pancreatic
Oncology 	Oncology
MK-1022 (patritumab deruxtecan)1
NSCLC (EU)
MK-1026 (nemtabrutinib)
Hematological Malignancies
MK-10842
NSCLC
MK-1308A (quavonlimab
+pembrolizumab)
RCC
MK-2140 (zilovertamab vedotin)
Hematological Malignancies
MK-2400 (ifinatamab deruxtecan)1
SCLC
MK-2870 (sacituzumab tirumotecan)1,3
Breast
Cervical
Endometrial
Gastric
NSCLC
MK-3543 (bomedemstat)
Myeloproliferative Disorders
KEYTRUDA (MK-3475)
Hepatocellular (EU)
Ovarian
SCLC
MK-3475A (pembrolizumab +
berahyaluronidase alfa)
NSCLC
MK-5684 (opevesostat)
Prostate
LYNPARZA (MK-7339)1,2
NSCLC
SCLC
LENVIMA (MK-7902)1,2
Esophageal
V940 1,2
Melanoma
NSCLC
Infectious Disease
MK-8591A (doravirine+islatravir)5
HIV-1 Infection
MK-8591D (islatravir+lenacapavir)1,5
HIV-1 Infection
LAGEVRIO (MK-4482)1,6
COVID-19 Antiviral
MK-7240 (tulisokibart)
Crohn’s Disease
Ulcerative Colitis
Immunology
Cardiometabolic
MK-0616 (enlicitide decanoate)
Hypercholesterolemia
As of February 25, 2025
Oncology
KEYTRUDA (MK-3475)
Mesothelioma (EU, JPN)
MK-1022 (patritumab deruxtecan)1,8
NSCLC (US)
WELIREG (MK-6482)
Advanced RCC (JPN)
Certain VHL Tumors (JPN)
PPGL (US)
Vaccines
CAPVAXIVE (V116)
Pneumococcal Vaccine Adult (EU, JPN)
MK-3000 7
Diabetic Macular Edema
Ophthalmology
V181
Dengue Fever Virus
Vaccines
Infectious Disease
MK-8527
HIV-1 PrEP
MK-8591B (islatravir+MK-8507)4
HIV-1 Infection
MK-5475
PH-COPD
MK-6024 (efinopegdutide)
MASH
WINREVAIR (MK-7962)
Pulmonary Hypertension due to
Left Heart Disease
Cardiometabolic
MK-6194
Lupus
Vitiligo
MK-7240 (tulisokibart)
Systemic Sclerosis
Immunology
MK-1167
Alzheimer’s
Neuroscience
Infectious Disease
MK-1654 (clesrovimab)
Respiratory Syncytial Virus (US, EU)
Cardiometabolic
WINREVAIR (MK-7962)
Pulmonary Arterial Hypertension (JPN)
35	1. Being developed in a collaboration 2. Being developed in combination with KEYTRUDA 3. Being developed as monotherapy and/or in combination with KEYTRUDA 4. FDA lifted clinical hold on 12/4/2024 5. On partial clinical hold for higher doses of islatravir
than those used in current clinical trials 6. Available in the U.S. under Emergency Use Authorization 7. Program is in Phase 2/3 study 8. In June 2024, FDA issued a CRL for the BLA for patritumab deruxtecan. Merck is working with Daiichi Sankyo to address FDA
feedback

-- 35 of 35 --